This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Wrenda Teeple, PharmD
Advertisement
Articles by Wrenda Teeple, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Senate Unveils Sweeping Bill to Reform 340B Drug Program
2
Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD
3
Brexpiprazole and Dextromethorphan-Bupropion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies
4
Trump Childhood Vaccine Order: What It Means for Parents and Payers
5